{
  "authorized_claims": [
    {
      "market": "EFSA",
      "framework_reference": "Reg 432/2012",
      "claim_verbatim": "Protein contributes to a growth in muscle mass.",
      "authorization_date": "2012",
      "conditions": "Reg 1924/2006 art 10(2) + Annex: claim may only be used for food which is at least a \"source of protein\" — ≥ 12% of energy value provided by protein"
    },
    {
      "market": "EFSA",
      "framework_reference": "Reg 432/2012",
      "claim_verbatim": "Protein contributes to the maintenance of muscle mass.",
      "authorization_date": "2012",
      "conditions": "Reg 1924/2006 art 10(2) + Annex: claim may only be used for food which is at least a \"source of protein\" — ≥ 12% of energy value provided by protein"
    },
    {
      "market": "EFSA",
      "framework_reference": "Reg 432/2012",
      "claim_verbatim": "Protein contributes to the maintenance of normal bones.",
      "authorization_date": "2012",
      "conditions": "Reg 1924/2006 art 10(2) + Annex: claim may only be used for food which is at least a \"source of protein\" — ≥ 12% of energy value provided by protein"
    },
    {
      "market": "ANVISA",
      "framework_reference": "IN 28/2018 Anexo V alegação funcional",
      "claim_verbatim": "As proteínas auxiliam na formação dos músculos e ossos.",
      "authorization_date": "2018",
      "conditions": "IN 28/2018 Anexo V: alegação restrita aos suplementos cuja quantidade de proteína e perfil de aminoácidos essenciais atendam os Anexos III + VII"
    }
  ],
  "slug": "plant-protein",
  "name": "Plant Protein Blend (Pea + Rice + Hemp + Soy combinations)",
  "alternate_names": [
    "Vegan protein blend",
    "Plant-based protein",
    "Multi-source plant protein"
  ],
  "mechanism": [
    "Combination of plant proteins balances limiting amino acids (legume methionine deficit complemented by cereal lysine deficit)",
    "Leucine threshold reached at higher absolute doses (~30-40 g) than dairy-based proteins",
    "mTORC1 activation comparable to milk protein when blended and dose-matched"
  ],
  "target": [
    "Skeletal muscle protein synthesis",
    "Plant-based dietary protein adequacy",
    "Whole-body amino acid balance for diverse diets"
  ],
  "use_case": [
    "plant-based diet protein adequacy",
    "dairy / animal allergen avoidance",
    "sustainable dietary pattern support",
    "sarcopenia prevention"
  ],
  "body_system": [
    "MUSCULO",
    "METABOLISM"
  ],
  "evidence_tier": "B",
  "evidence_anchor_pmid_count": 2,
  "dosage_range": "30-40 g per serving (Reid-McCann 2025 PMID 39813010 Nutrition Reviews SR + meta-analysis of 43 RCT · 30 in meta showed animal protein favoured for muscle mass while no significant difference for muscle strength); 1.2-1.6 g/kg/day total when relying on plant blends",
  "safety_notes": "Common plant allergens may be present depending on the blend formula (soy / pea / wheat); blends should disclose individual sources for allergen-aware adults; PDCAAS varies by formulation with well-formulated blends approaching 0.9-1.0",
  "regulatory": {
    "fda": "GRAS · DSHEA dietary supplement · no specific health claim · qualifies for 21 CFR 101.79 \"good source of protein\" (≥ 10% DV) when serving size meets the threshold",
    "efsa": "Authorized protein claims (Reg 432/2012) for muscle mass + bone maintenance available when food source provides ≥ 12% energy from protein",
    "anvisa": "RDC 243/2018 dietary supplement · IN 28/2018 Anexo V alegação funcional verbatim: \"As proteínas auxiliam na formação dos músculos e ossos.\" (Anexo III ≥ 8,4 g/dia adultos ≥ 19 anos · Anexo VII proteína de referência AAE/g)"
  },
  "ingredient_hub_url": "https://asxan.ai/ingredients/plant-protein/",
  "related_goal_slugs": [
    "athletic-performance",
    "weight-management",
    "longevity-stack",
    "menopause-support"
  ],
  "related_lifestyle_slugs": [
    "plant-based",
    "athletic-performance",
    "senior-60-plus"
  ],
  "last_evidence_review": "2026-06-04",
  "schema_version": "nc-public-v0.2",
  "api_version": "nc-public-v0.3",
  "_meta": {
    "last_evidence_review": "2026-06-04",
    "ip_axes_disclosed": {
      "public_axes": [
        "mechanism",
        "target",
        "use_case",
        "body_system",
        "evidence_tier",
        "dosage_range",
        "safety_notes",
        "regulatory",
        "authorized_claims"
      ],
      "ip_axes_not_exposed": [
        "proprietary_formula_ratios",
        "clinical_protocol_internals",
        "rnd_pipeline_compounds",
        "supplier_specific_grade_specifications",
        "unpublished_endpoint_data"
      ],
      "rationale": "asxan.ai surfaces the educational, evidence-tier-disclosed slice. Formula composition, clinical-protocol internals, and RnD pipeline data are intentionally outside this public surface."
    }
  }
}